{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:45:14Z","timestamp":1780983914570,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2002,7,22]],"date-time":"2002-07-22T00:00:00Z","timestamp":1027296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objective<\/jats:title><jats:p>Selective serotonin reuptake inhibitors (SSRIs) are currently the first\u2010line treatment for panic disorder, although up to 30% of patients either do not respond to SSRIs or withdraw due to adverse events. Reboxetine, a selective norepinephrine reuptake inhibitor (selective NRI), is effective in treating depression and may alleviate depression\u2010related anxiety. This study aimed to investigate the efficacy of reboxetine in the treatment of patients with panic disorder who did not respond to SSRIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In this 6\u2010week, open\u2010label study, 29 adult outpatients with panic disorder who had previously failed to respond to SSRI treatment received reboxetine 2\u2009mg\/day, titrated to a maximum of 8\u2009mg\/day over the first 10 days. Efficacy was assessed using the Panic Self\u2010Questionnaire (PSQ), the Hamilton Rating Scale for Anxiety (HAM\u2010A), the 17\u2010item Hamilton Rating Scale for Depression (HRSD) and the Global Assessment of Functioning (GAF) Scale.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 24 patients who completed the study responded well to reboxetine treatment. Significant improvement (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) was observed in the number of daily panic attacks, and on the scales measuring anxiety, depression and functioning. Reboxetine was generally well tolerated. Five patients withdrew due to adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Reboxetine appears to be effective in the treatment of SSRI\u2010refractory panic disorder patients and warrants further clinical investigation. Copyright \u00a9 2002 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.421","type":"journal-article","created":{"date-parts":[[2002,11,4]],"date-time":"2002-11-04T13:53:35Z","timestamp":1036418015000},"page":"329-333","source":"Crossref","is-referenced-by-count":29,"title":["The efficacy of reboxetine in the treatment\u2010refractory patients with panic disorder: an open label study"],"prefix":"10.1002","volume":"17","author":[{"given":"P. N.","family":"Dannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Iancu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Grunhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,7,22]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/107385849800400111"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00300-X"},{"key":"e_1_2_1_4_1","unstructured":"DannonP IancuI GrunhausL.Efficacy of reboxetine in the treatment of SSRI\u2010resistant panic disorder.American Psychiatric Association Annual Meeting 5\u201310 May 2001 New Orleans USA(Abstr.)."},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00014-1"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-198801000-00005"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2000.00003.x"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(92)90094-M"},{"issue":"2","key":"e_1_2_1_9_1","first-page":"4","article-title":"Toward an integrated neurobiology of panic disorder","volume":"58","author":"Goddard AW","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"14","key":"e_1_2_1_10_1","first-page":"54","article-title":"The use of newer antidepressants for panic disorder","volume":"58","author":"Gorman JM","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198710000-00007"},{"issue":"2","key":"e_1_2_1_12_1","first-page":"24","article-title":"Antidepressants in panic disorder","volume":"58","author":"Jefferson JW","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549030-00002"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(91)90003-B"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.119.5.432"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb00388.x"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb00389.x"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n1006"},{"issue":"13","key":"e_1_2_1_19_1","first-page":"5","article-title":"Panic disorder as a chronic illness","volume":"58","author":"Liebowitz MR","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.173.1.54"},{"key":"e_1_2_1_21_1","first-page":"183","article-title":"Preliminary report: placebo\u2010controlled, double\u2010blind study of the clinical effects of desipramine in panic disorder","volume":"29","author":"Lydiard RB","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n0103"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810020029006"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90198-3"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.167.3.374"},{"issue":"10","key":"e_1_2_1_26_1","first-page":"31","article-title":"Clinical efficacy of reboxetine in major depression","volume":"61","author":"Schatzberg A","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2000.02604.x"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0107"},{"key":"e_1_2_1_29_1","unstructured":"VersianiM MontgomerySA StahlS SchwartzGS.2000.The effect of reboxetine on anxiety.American College of Neuropsychopharmacology Annual Meeting 10\u201314 December 2000 Puerto Rico(Abstr.)."},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830160021003"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.421","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T14:39:29Z","timestamp":1700231969000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,22]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1002\/hup.421"],"URL":"https:\/\/doi.org\/10.1002\/hup.421","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7,22]]}}}